Franklin Resources Inc. Acquires 395,744 Shares of Sanofi (NASDAQ:SNY)

Franklin Resources Inc. increased its holdings in shares of Sanofi (NASDAQ:SNY) by 13.1% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,407,452 shares of the company’s stock after buying an additional 395,744 shares during the quarter. Franklin Resources Inc.’s holdings in Sanofi were worth $208,106,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the business. Stablepoint Partners LLC boosted its holdings in shares of Sanofi by 0.8% during the 3rd quarter. Stablepoint Partners LLC now owns 23,893 shares of the company’s stock valued at $1,377,000 after acquiring an additional 189 shares in the last quarter. PDS Planning Inc lifted its holdings in shares of Sanofi by 3.1% during the third quarter. PDS Planning Inc now owns 6,643 shares of the company’s stock worth $383,000 after purchasing an additional 200 shares during the period. Eagle Ridge Investment Management increased its holdings in Sanofi by 3.8% in the third quarter. Eagle Ridge Investment Management now owns 5,571 shares of the company’s stock valued at $321,000 after purchasing an additional 203 shares during the period. Financial Advocates Investment Management lifted its holdings in Sanofi by 3.4% during the 3rd quarter. Financial Advocates Investment Management now owns 6,327 shares of the company’s stock worth $365,000 after buying an additional 206 shares during the period. Finally, Angeles Investment Advisors LLC increased its stake in shares of Sanofi by 1.9% in the third quarter. Angeles Investment Advisors LLC now owns 11,323 shares of the company’s stock valued at $653,000 after buying an additional 210 shares during the period. 14.04% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have recently issued reports on SNY shares. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday. Citigroup upgraded Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Two research analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Sanofi currently has a consensus rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Trading Down 0.4 %

NASDAQ SNY opened at $46.80 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $118.77 billion, a P/E ratio of 23.88, a PEG ratio of 1.24 and a beta of 0.58. The business has a fifty day simple moving average of $51.02 and a 200 day simple moving average of $52.07. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The company had revenue of $13.44 billion during the quarter, compared to the consensus estimate of $16.59 billion. Sanofi’s revenue was up 12.3% on a year-over-year basis. During the same period last year, the business posted $2.55 earnings per share. On average, analysts predict that Sanofi will post 4.27 EPS for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.